Dr. Al Zoughbi is a certified anatomic pathologist with experience in translational molecular oncology. For the last ten years he has been applying his skills in pathology at the interface between medicine, science, and enterprise to guide precision cancer medicine and tissue-based biomarker discovery.
What makes your research unique?
It is the integrated system of experience in clinical applications and technology innovation that will shape the future of medicine. Hence, I am excited to be here at the Englander Institute for Precision Medicine (EIPM).
What excites you about your work?
As both a clinician and scientist, I was in direct contact not only with cancer patients but also with their families. The responsibility I felt toward them provided motivation and energy to my work. Being a Research Pathology Fellow at the Weill Cornell Medicine Department of Pathology and Laboratory Medicine provides the opportunity to collaborate with several groups with diverse academic experience on a common aim to ultimately improve the quality of a cancer patient’s life—this is a powerful source of inspiration for me.
What are some of the breakthroughs that are propelling the field forward?
There have been remarkable individual breakthroughs in pathology, but the combination of these discoveries, coupled with the potential of precision medicine, together hold the most promise for propelling the field forward.
What else would you like to share with your new colleagues at the Englander Institute for Precision Medicine?
It is a privilege to start working here, and I look forward to collaborating with all of my new colleagues to revolutionize healthcare. Equally important is my family, and making sure my daughter understands this work and is hopefully proud of me.
# # #